Twinrix Adult

Hepatitis A (inactivated) & hepatitis B (rDNA) vaccine (adsorbed)

For use in non-immune adults & adolescents ≥16 yr who are at risk of both hepatitis A & B infections.

Adult & adolescent ≥16 yr 1 mL (1 dose) by IM, preferably in the deltoid region. Primary vaccination schedule 3 doses: The 1st dose administered at the elected date, the 2nd dose 1 mth later & the 3rd dose 6 mth after the 1st dose. In situations where a booster dose of both hepatitis A & B are desired, Twinrix Adult can be given. Travel vaccination schedule (w/ insufficient time for standard 0, 1, 6 mth schedule) 3 inj at 0, 7 & 21 days may be used, then the 4th dose is at 12 mth after the 1st dose.

Hypersensitivity to any component of the vaccine or neomycin, or after previous administration of hepatitis A &/or B vaccines.

Postpone vaccination in subjects suffering from acute severe febrile illness. Not recommended for postexposure prophylaxis (eg, needle stick injury). Haemodialysis patients & persons w/ impaired immune system may require administration of additional dose. Obesity (BMI ≥ 30 kg/m²) has been observed to reduce the immune response to hepatitis A vaccines. Immune response to HBV vaccine may vary due to a number of factors including older age, male gender, obesity, smoking, route of administration, & some chronic underlying diseases. Additional doses may need to be considered for persons who do not respond or have a sub-optimal response to a course of vaccinations. Avoid intradermal inj or IM administration into the gluteal muscle. Administer SC to patients w/ thrombocytopenia or bleeding disorders since bleeding may occur following IM administration. Do not administer intravascularly. Appropriate medical treatment & supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine. Protective immune response may not be elicited in all vaccinees. Pregnancy & lactation.

Headache; pain & redness at the inj site, fatigue. GI symptoms, diarrhoea, nausea; swelling at the inj site, inj site reactions (eg, haematoma, pruritus, bruising), malaise.

Although concomitant administration w/ other vaccines has not specifically been studied, it is anticipated that, if different syringes & other inj sites are used, no interaction will be observed. Adequate response may not be achieved in patients receiving immunosuppressive therapy.

Vaccines, Antisera & Immunologicals

J07BC20 - combinations ; Belongs to the class of hepatitis viral vaccines.

P₁S₁S₃, A